Literature DB >> 3980659

Ion-paired high-performance liquid chromatographic determination of mitoxantrone in physiological fluids.

S J van Belle, T J Schoemaker, S L Verwey, A C Paalman, J G McVie.   

Abstract

Mitoxantrone is one of the newer anthracenedione derivatives which has already been studied in phase I and II trials, where it has shown significant antitumor activity against a variety of human tumours. To determine the prolonged terminal half-life of mitoxantrone, we developed a sensitive high-performance liquid chromatographic method, providing a detection limit of 1 ng/ml of extracted serum. This system uses a C18 reversed-phase column. The mobile phase consists of a mixture of acetonitrile (30%, v/v) and an ammonium formate buffer (70%, v/v) with a pH of 2.7. Hexane sulphonic acid is added as an ion-pair former. Detection at a wavelength of 658 nm provides a highly selective system, showing no interfering peaks. Ametantrone, another anthracenedione derivative, is used as an internal standard. The extraction procedure for serum also uses hexane sulphonic acid in an ion-paired system. Because of the highly selective detection wavelength, urine samples can be injected without a sample clean-up procedure. This very sensitive method, combined with high selectivity and a fast and inexpensive serum clean-up procedure, has allowed us to document the prolonged terminal plasma half-life of mitoxantrone (levels of 2-5 ng/ml of plasma can still be detected six days after an intravenous infusion of 15 mg/m2 over 30 min). In urine an as yet unidentified metabolite was discovered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980659     DOI: 10.1016/0378-4347(85)80009-8

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

1.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.

Authors:  J D Nagel; I Krüger; F Ghussen; U Bode
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.

Authors:  J H Schiller; B Storer; R Arzoomanian; K Tutsch; D Alberti; D Spriggs
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

5.  Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy.

Authors:  S J Van Belle; M M de Planque; I E Smith; A T van Oosterom; T J Schoemaker; W Deneve; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer.

Authors:  M O Nicoletto; R Padrini; H Koussis; A Rosabian; S Aversa; L Endrizzi; P Azzoni; M Palumbo; M V Fiorentino
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.